89bio Ownership
| ETNB Stock | USD 8.96 0.20 2.28% |
Shares in Circulation | First Issued 2018-09-30 | Previous Quarter 99.8 M | Current Value 107.1 M | Avarage Shares Outstanding 36.5 M | Quarterly Volatility 33.3 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
89bio |
89bio Stock Ownership Analysis
About 94.0% of the company shares are held by institutions such as insurance companies. The book value of 89bio was currently reported as 3.56. The company recorded a loss per share of 2.96. 89bio Inc had not issued any dividends in recent years. 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California. 89Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people. To learn more about 89bio Inc call Rohan Palekar at 415 432 9270 or check out https://www.89bio.com.Besides selling stocks to institutional investors, 89bio also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different 89bio's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align 89bio's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
89bio Quarterly Liabilities And Stockholders Equity |
|
89bio Insider Trades History
Less than 1% of 89bio Inc are currently held by insiders. Unlike 89bio's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against 89bio's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of 89bio's insider trades
89bio Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as 89bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading 89bio Inc backward and forwards among themselves. 89bio's institutional investor refers to the entity that pools money to purchase 89bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Citadel Advisors Llc | 2024-09-30 | 2.6 M | Geode Capital Management, Llc | 2024-09-30 | 2.1 M | Redmile Group, Llc | 2024-09-30 | 1.6 M | Millennium Management Llc | 2024-06-30 | 1 M | Goldman Sachs Group Inc | 2024-06-30 | 904.8 K | Exoduspoint Capital Management, Lp | 2024-09-30 | 871.4 K | Candriam Luxembourg S.c.a. | 2024-06-30 | 848.1 K | Laurion Capital Management Lp | 2024-09-30 | 810.5 K | Alyeska Investment Group, L.p. | 2024-09-30 | 808.6 K | Ra Capital Management, Llc | 2024-09-30 | 14.2 M | Hhg Plc | 2024-06-30 | 13.3 M |
89bio Inc Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific 89bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on 89bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases 89bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
89bio Outstanding Bonds
89bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. 89bio Inc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most 89bio bonds can be classified according to their maturity, which is the date when 89bio Inc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
89bio Corporate Filings
F4 | 25th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 14th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 13th of November 2024 Other Reports | ViewVerify | |
13A | 8th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether 89bio Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of 89bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of 89bio Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on 89bio Inc Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in 89bio Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 89bio. If investors know 89bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 89bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.96) | Return On Assets (0.41) | Return On Equity (0.73) |
The market value of 89bio Inc is measured differently than its book value, which is the value of 89bio that is recorded on the company's balance sheet. Investors also form their own opinion of 89bio's value that differs from its market value or its book value, called intrinsic value, which is 89bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 89bio's market value can be influenced by many factors that don't directly affect 89bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 89bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if 89bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 89bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.